EUVIMEDEUVIMED entdecken
Open Access · CC BY 4.0

Neddylation inhibition sensitises renal medullary carcinoma tumours to platinum chemotherapy

Daniel D Shapiro iD, Niki Millward Zacharias iD, Durga N Tripathi, Menuka Karki, Jean-Philippe Bertocchio, Melinda Soeung, Rong He, Mary E Westerman, Jianjun Gao, Priya Rao, Truong N A Lam, Eric Jonasch und 9 weitere

Clinical and Translational Medicine · 2023-05 · 13 (5)

DOI: 10.1002/ctm2.1267 ↗

Kurz gefasst

Fachartikel in der Zeitschrift Clinical and Translational Medicine, online erschienen am 25.05.2023. Verfasst von Daniel D Shapiro und 20 weiteren Autor:innen. Beteiligte Einrichtung: Department of Urology, University of Wisconsin School of Medicine and Public Health, Madison, Wisconsin, USA. Hauptthemen laut MEDLINE: Carcinoma, Medullary, Carcinoma, Renal Cell, Kidney Neoplasms. Die Arbeit wurde bisher 17-mal zitiert (Crossref) und nennt 43 Literaturangaben. Der Volltext ist frei zugänglich (Open Access, CC BY 4.0). Gefördert von: NCI NIH HHS, Philippe Foundation.

AbstractSchlagwörterBibliografische AngabenZitierenVerwandte Studien

Abstract (Originalsprache)

Background

Renal medullary carcinoma (RMC) is a highly aggressive cancer in need of new therapeutic strategies. The neddylation pathway can protect cells from DNA damage induced by the platinum‐based chemotherapy used in RMC. We investigated if neddylation inhibition with pevonedistat will synergistically enhance antitumour effects of platinum‐based chemotherapy in RMC.

Methods

We evaluated the IC 50 concentrations of the neddylation‐activating enzyme inhibitor pevonedistat in vitro in RMC cell lines. Bliss synergy scores were calculated using growth inhibition assays following treatment with varying concentrations of pevonedistat and carboplatin. Protein expression was assessed by western blot and immunofluorescence assays. The efficacy of pevonedistat alone or in combination with platinum‐based chemotherapy was evaluated in vivo in platinum‐naïve and platinum‐experienced patient‐derived xenograft (PDX) models of RMC.

Results

The RMC cell lines demonstrated IC 50 concentrations of pevonedistat below the maximum tolerated dose in humans. When combined with carboplatin, pevonedistat demonstrated a significant in vitro synergistic effect. Treatment with carboplatin alone increased nuclear ERCC1 levels used to repair the interstrand crosslinks induced by platinum salts. Conversely, the addition of pevonedistat to carboplatin led to p53 upregulation resulting in FANCD2 suppression and reduced nuclear ERCC1 levels. The addition of pevonedistat to platinum‐based chemotherapy significantly inhibited tumour growth in both platinum‐naïve and platinum‐experienced PDX models of RMC ( p < .01).

Conclusions

Our results suggest that pevonedistat synergises with carboplatin to inhibit RMC cell and tumour growth through inhibition of DNA damage repair. These findings support the development of a clinical trial combining pevonedistat with platinum‐based chemotherapy for RMC.

Schlagwörter

MeSH-Schlagwörter (MEDLINE)

Carcinoma, MedullaryCarcinoma, Renal CellKidney NeoplasmsHumansCarboplatinCyclopentanesPyrimidines

Stichwörter der Autor:innen

chemotherapyneddylationpevonedistatrenal medullary carcinoma

Substanzen

CarboplatinpevonedistatCyclopentanesPyrimidines

Autor:innen und Institutionen

  • Department of Urology, University of Wisconsin School of Medicine and Public Health, Madison, Wisconsin, USA.
  • Division of Urology, William S. Middleton Memorial Veterans Hospital, Madison, Wisconsin, USA.
  • Department of Urology, The University of Texas MD Anderson Cancer Center, Houston, Texas, USA.
  • Center for Precision Environmental Health, Baylor College of Medicine, Houston, Texas, USA.
  • Department of Genitourinary Medical Oncology, The University of Texas MD Anderson Cancer Center, Houston, Texas, USA.
  • Department of Pathology, The University of Texas MD Anderson Cancer Center, Houston, Texas, USA.

ORCID-Profile: Daniel D Shapiro, Niki Millward Zacharias, Pavlos Msaouel

Förderung

  • NCI NIH HHS
  • Philippe Foundation

Zitieren

APA

Shapiro, D. D., Zacharias, N. M., Tripathi, D. N., Karki, M., Bertocchio, J. P., Soeung, M., He, R., Westerman, M. E., Gao, J., Rao, P., Lam, T. N. A., Jonasch, E., Perelli, L., Cheng, E. H., Carugo, A., Heffernan, T. P., Walker, C. L., Genovese, G., Tannir, N. M., …, & Msaouel, P. (2023). Neddylation inhibition sensitises renal medullary carcinoma tumours to platinum chemotherapy. Clinical and Translational Medicine, 13(5). https://doi.org/10.1002/ctm2.1267

Vancouver

Shapiro DD, Zacharias NM, Tripathi DN, Karki M, Bertocchio JP, Soeung M, et al. Neddylation inhibition sensitises renal medullary carcinoma tumours to platinum chemotherapy. Clinical and Translational Medicine. 2023;13(5). doi:10.1002/ctm2.1267

BibTeX
@article{Shapiro2023,
  author = {Shapiro, Daniel D and Zacharias, Niki Millward and Tripathi, Durga N and Karki, Menuka and Bertocchio, Jean-Philippe and Soeung, Melinda and He, Rong and Westerman, Mary E and Gao, Jianjun and Rao, Priya and Lam, Truong N A and Jonasch, Eric and Perelli, Luigi and Cheng, Emily H and Carugo, Alessandro and Heffernan, Timothy P and Walker, Cheryl L and Genovese, Giannicola and Tannir, Nizar M and Karam, Jose A and Msaouel, Pavlos},
  title = {Neddylation inhibition sensitises renal medullary carcinoma tumours to platinum chemotherapy},
  journal = {Clinical and Translational Medicine},
  year = {2023},
  volume = {13},
  number = {5},
  doi = {10.1002/ctm2.1267}
}
Kostenlos starten →